

Table 2. Pulmonary Toxicity Associated with Cytotoxic Antibiotics

Cytotoxic Antibiotic	Clinical syndromes	Potential risk factors
Bleomycin	<ul style="list-style-type: none"> • Interstitial pneumonitis/ pulmonary fibrosis 	<ul style="list-style-type: none"> • cumulative dose > 400 units • older age • concurrent, prior, or post-treatment thoracic irradiation • renal insufficiency • concomitant treatment with other cytotoxic agents • exposure to high concentrations of inspired oxygen
	<ul style="list-style-type: none"> • Hypersensitivity-type pneumonitis 	
	<ul style="list-style-type: none"> • Acute chest pain syndrome 	
Mitomycin-C	<ul style="list-style-type: none"> • Acute interstitial pneumonitis 	<ul style="list-style-type: none"> • Combination treatment with vinca alkaloids
	<ul style="list-style-type: none"> • Chronic interstitial pneumonitis/pulmonary fibrosis 	<ul style="list-style-type: none"> • High cumulative dose (> 20 mg/m²)
	<ul style="list-style-type: none"> • Microangiopathic hemolytic anemia with or without pulmonary hemorrhage 	
	<ul style="list-style-type: none"> • Acute bronchospasm 	<ul style="list-style-type: none"> • Occurs in temporal association with drug administration
	<ul style="list-style-type: none"> • Pulmonary veno-occlusive disease 	
Actinomycin-D	<ul style="list-style-type: none"> • Exacerbation of radiation-induced lung injury 	<ul style="list-style-type: none"> • Therapeutic thoracic irradiation